After exclusion of reactive processes, carcinomas, and mesenchymal neoplasms, additional EMA, desmin, IMP‐3, and thrombomodulin positivity can be observed in the majority of cases, alongside with BAP1 loss. The gene discussed is DES; the disease is mesenchymal cell neoplasm.